Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (53) 53
oncology (50) 50
humans (47) 47
male (35) 35
middle aged (35) 35
aged (33) 33
female (33) 33
article (31) 31
lung neoplasms - drug therapy (25) 25
lung neoplasms - pathology (24) 24
aged, 80 and over (23) 23
adult (22) 22
lung neoplasms - genetics (21) 21
mutation (21) 21
respiratory system (20) 20
lung cancer (19) 19
neoplasm staging (19) 19
carcinoma, non-small-cell lung - drug therapy (16) 16
chemotherapy (15) 15
cancer (14) 14
lung neoplasms - mortality (13) 13
treatment outcome (13) 13
adenocarcinoma - genetics (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
immunotherapy (12) 12
prognosis (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
neoadjuvant therapy (11) 11
tumors (11) 11
adenocarcinoma - pathology (10) 10
adenocarcinoma of lung (10) 10
docetaxel (10) 10
erbb receptors - genetics (10) 10
lung cancer, non-small cell (10) 10
nivolumab (10) 10
open-label (10) 10
survival (10) 10
antineoplastic agents - therapeutic use (9) 9
carcinoma, non-small-cell lung - mortality (9) 9
gefitinib (9) 9
hematology, oncology and palliative medicine (9) 9
therapy (9) 9
adjuvant chemotherapy (8) 8
egfr (8) 8
multicenter (8) 8
non-small cell lung cancer (8) 8
surgery (8) 8
trial (8) 8
antibodies, monoclonal - therapeutic use (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
cell lung-cancer (7) 7
gene expression (7) 7
lung neoplasms - surgery (7) 7
lung neoplasms - therapy (7) 7
pembrolizumab (7) 7
pulmonary and respiratory medicine (7) 7
adenocarcinoma (6) 6
care and treatment (6) 6
lung adenocarcinoma (6) 6
nsclc (6) 6
patients (6) 6
preoperative chemotherapy (6) 6
pulmonary/respiratory (6) 6
resistance (6) 6
survival analysis (6) 6
young adult (6) 6
adenocarcinoma - drug therapy (5) 5
adenocarcinoma - mortality (5) 5
afatinib (5) 5
antibodies, monoclonal - adverse effects (5) 5
bevacizumab (5) 5
carcinoma, non-small-cell lung - surgery (5) 5
chemotherapy, adjuvant (5) 5
induction chemotherapy (5) 5
ipilimumab (5) 5
lung neoplasms - diagnosis (5) 5
medical colleges (5) 5
neoadjuvant chemotherapy (5) 5
non-small-cell lung cancer (5) 5
original reports (5) 5
phase-ii trial (5) 5
protein kinase inhibitors - therapeutic use (5) 5
proto-oncogene proteins - genetics (5) 5
ras proteins - genetics (5) 5
receptor protein-tyrosine kinases - genetics (5) 5
vinorelbine plus cisplatin (5) 5
abridged index medicus (4) 4
adenocarcinomas (4) 4
apoptosis (4) 4
b7-h1 antigen - antagonists & inhibitors (4) 4
b7-h1 antigen - immunology (4) 4
cancer therapies (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - therapy (4) 4
cardiac & cardiovascular systems (4) 4
cell biology (4) 4
drug resistance, neoplasm (4) 4
erlotinib (4) 4
follow-up studies (4) 4
health aspects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
by Shaverdian, Narek and Offin, Michael D and Rimner, Andreas and Shepherd, Annemarie F and Wu, Abraham J and Rudin, Charles M and Hellmann, Matthew D and Chaft, Jamie E and Gomez, Daniel R
Radiotherapy and Oncology, ISSN 0167-8140, 03/2020, Volume 144, pp. 101 - 104
Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data... 
Consolidative durvalumab | Chemoradiation | Non-small cell lung cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text EA5142 adjuvant nivolumab in resected lung cancers (ANVIL)
by Chaft, Jamie E and Dahlberg, Suzanne Eleanor and Khullar, Onkar V and Edelman, Martin J and Simone, Charles B and Heymach, John and Rudin, Charles M and Ramalingam, Suresh S
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. TPS8581 - TPS8581
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease
by Hellmann, Matthew David and Zhang, Qu and Abdullah, Shaad Essa and Chaft, Jamie E and Segal, Neil Howard and Gao, Chen and Dennis, Phillip A and Higgs, Brandon W
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 2546 - 2546
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
by Zhang, Jiajia and Ji, Zhicheng and Caushi, Justina X and El Asmar, Margueritta and Anagnostou, Valsamo and Cottrell, Tricia R and Chan, Hok Yee and Suri, Prerna and Guo, Haidan and Merghoub, Taha and Chaft, Jamie E and Reuss, Joshua E and Tam, Ada J and Blosser, Richard L and Abu-Akeel, Mohsen and Sidhom, John-William and Zhao, Ni and Ha, Jinny S and Jones, David R and Marrone, Kristen A and Naidoo, Jarushka and Gabrielson, Edward and Taube, Janis M and Velculescu, Victor E and Brahmer, Julie R and Housseau, Franck and Hellmann, Matthew D and Forde, Patrick M and Pardoll, Drew M and Ji, Hongkai and Smith, Kellie N
Clinical Cancer Research, ISSN 1078-0432, 11/2019, p. clincanres.2931.2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
by Antonia, Scott, Prof and Goldberg, Sarah B, MD and Balmanoukian, Ani, MD and Chaft, Jamie E, MD and Sanborn, Rachel E, MD and Gupta, Ashok, MD and Narwal, Rajesh, PhD and Steele, Keith, PhD and Gu, Yu, PhD and Karakunnel, Joyson J, MD and Rizvi, Naiyer A, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 299 - 308
Summary Background PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and... 
Hematology, Oncology and Palliative Medicine | TRIAL | ANTIBODY | ONCOLOGY | NIVOLUMAB | MEDI4736 | IPILIMUMAB | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Lung Neoplasms - pathology | Male | Dose-Response Relationship, Drug | Young Adult | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Viral antibodies | Biological products | Safety and security measures | Oncology, Experimental | Antibodies | Lung cancer, Small cell | Research | T cells | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Outcomes with chemotherapies and molecular characteristics of HER2-mutant lung cancers
by Eng, Juliana and Li, Bob T and Hsu, Meier and Chaft, Jamie E and Arcila, Maria E and Kris, Mark G
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 8068 - 8068
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC
by Forde, Patrick M and Chaft, Jamie E and Felip, Enriqueta and Broderick, Stephen and Girard, Nicolas and Awad, Mark M and Kerr, Keith and Blackwood-Chirchir, Anne and Yang, Rong and Geese, William J and Brahmer, Julie R
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. TPS8577 - TPS8577
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Adaptive Neoadjuvant Chemotherapy Guided by 18F-FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial
by Chaft, Jamie E and Dunphy, Mark and Naidoo, Jarushka and Travis, William D and Hellmann, Matthew and Woo, Kaitlin and Downey, Robert and Rusch, Valerie and Ginsberg, Michelle S and Azzoli, Christopher G and Kris, Mark G
Journal of Thoracic Oncology, ISSN 1556-0864, 04/2016, Volume 11, Issue 4, pp. 537 - 544
Although perioperative chemotherapy improves survival in patients with resectable lung cancers, systemic recurrence remains common. Neoadjuvant chemotherapy... 
Neoadjuvant therapy | Non–small cell lung cancer | Adaptive clinical trial | 18F-FDG PET | F-FDG PET | Non-small cell lung cancer | non-small cell lung cancer | 18FDG-PET
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC)
by Cottrell, Tricia R and Stein, Julie E and Chaft, Jamie E and Thompson, Elizabeth D and Rekhtman, Natasha and Anagnostou, Valsamo and Smith, Kellie N and Duffield, Amy S and Anders, Robert A and Isbell, James M and Jones, David R and Cuda, Jonathan D and Battafarano, Richard and Yang, Stephen C and Illei, Peter B and Gabrielson, Edward and Askin, Frederic and Velez, Moises and Hellmann, Matthew D and Sauter, Jennifer L and Danilova, Ludmila and Velculescu, Victor E and Wolchok, Jedd D and Topalian, Suzanne L and Brahmer, Julie R and Pardoll, Drew M and Cimino-Mathews, Ashley and Forde, Patrick M and Taube, Janis M
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. LB-154 - LB-154
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
by Dagogo-Jack, Ibiayi and Santini, Fernando and Eng, Juliana and Yeap, Beow Y and Izar, Benjamin and Chin, Emily and Litvak, Anya and Jones, David Randolph and Kris, Mark G and Shaw, Alice Tsang and Gainor, Justin F and Chaft, Jamie E
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 8536 - 8536
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase II trial of bortezomib in KRAS G12D mutant lung cancers
by Litvak, Anna Maria and Drilon, Alexander E and Rekhtman, Natasha and Pietanza, Maria Catherine and Chaft, Jamie E and Woo, Kaitlin and Paik, Paul K and Kris, Mark G and Riely, Gregory J
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e19002 - e19002
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
by Forde, Patrick M and Chaft, Jamie E and Smith, Kellie N and Anagnostou, Valsamo and Cottrell, Tricia R and Hellmann, Matthew D and Zahurak, Marianna and Yang, Stephen C and Jones, David R and Broderick, Stephen and Battafarano, Richard J and Velez, Moises J and Rekhtman, Natasha and Olah, Zachary and Naidoo, Jarushka and Marrone, Kristen A and Verde, Franco and Guo, Haidan and Zhang, Jiajia and Caushi, Justina X and Chan, Hok Yee and Sidhom, John-William and Scharpf, Robert B and White, James and Gabrielson, Edward and Wang, Hao and Rosner, Gary L and Rusch, Valerie and Wolchok, Jedd D and Merghoub, Taha and Taube, Janis M and Velculescu, Victor E and Topalian, Suzanne L and Brahmer, Julie R and Pardoll, Drew M
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
In a pilot study, two doses of neoadjuvant nivolumab administered to patients with resectable lung cancer resulted in a major pathological response in 45% and... 
MISMATCH-REPAIR DEFICIENCY | TRIAL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PEMBROLIZUMAB | RESPONSE CRITERIA | SOLID TUMORS | IMMUNE CHECKPOINT BLOCKADE | IMMUNOTHERAPY | OPEN-LABEL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Neoadjuvant Therapy | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - surgery | Carcinoma, Non-Small-Cell Lung - genetics | Pilot Projects | B7-H1 Antigen - antagonists & inhibitors | Biopsy | Nivolumab | Lung Neoplasms - surgery | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug therapy | Lung cancer | Peptides | PD-1 protein | Body weight | Lymphocytes T | Cancer therapies | Lymphocytes | Immunotherapy | Surgery | Peripheral blood | Drug dosages | Antigens | Lymphatic system | Cell survival | Cloning | Feasibility studies | Non-small cell lung carcinoma | T cell receptors | Gene expression | Patients | Side effects | Chemotherapy | PD-L1 protein | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
by Valiente, Manuel and Obenauf, Anna C and Jin, Xin and Chen, Qing and Zhang, Xiang H.-F and Lee, Derek J and Chaft, Jamie E and Kris, Mark G and Huse, Jason T and Brogi, Edi and Massagué, Joan
Cell, ISSN 0092-8674, 02/2014, Volume 156, Issue 5, pp. 1002 - 1016
Brain metastasis is an ominous complication of cancer, yet most cancer cells that infiltrate the brain die of unknown causes. Here, we identify plasmin from... 
BREAST-CANCER | SYSTEM | FAS LIGAND | LUNG | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | INDUCED APOPTOSIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | MELANOMA-CELLS | ADHESION MOLECULE L1 | EXPRESSION | CELL BIOLOGY | Fas Ligand Protein - metabolism | Plasminogen Activator Inhibitor 2 - genetics | Humans | Plasminogen Activators - metabolism | Lung Neoplasms - pathology | Brain Neoplasms - metabolism | Breast Neoplasms - metabolism | Brain - metabolism | Brain Neoplasms - secondary | Plasminogen Activator Inhibitor 2 - metabolism | Female | Neural Cell Adhesion Molecule L1 - metabolism | Neuropeptides - genetics | Fibrinolysin - metabolism | Carcinoma - secondary | Disease Models, Animal | Serpins - genetics | Serpins - metabolism | Cell Survival | Neuropeptides - metabolism | Adenocarcinoma - secondary | Animals | Breast Neoplasms - pathology | Mice, Nude | Brain - pathology | Cell Line, Tumor | Mice | Astrocytes - metabolism | Lung cancer | Metastasis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Defining the spectrum and "overlap" of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification, and HER2 mutation
by Li, Bob T and Ross, Dara S and Chaft, Jamie E and Hsu, Meier and Kako, Severine and Aisner, Dara L and Kris, Mark G and Varella-Garcia, Marileila and Arcila, Maria E
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 8067 - 8067
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Utility of 18F-FDG PET and CT to assess response to neoadjuvant chemotherapy
by Chaft, Jamie E and Naidoo, Jarushka and Dunphy, Mark and Woo, Kaitlin and Sima, Camelia S and Downey, Robert J and Travis, William D and Kris, Mark G
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 7548 - 7548
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
by Chaft, Jamie E and Oxnard, Geoffrey R and Sima, Camelia S and Kris, Mark G and Miller, Vincent A and Riely, Gregory J
Clinical Cancer Research, ISSN 1078-0432, 10/2011, Volume 17, Issue 19, pp. 6298 - 6303
Purpose: Treatment of patients with oncogene-addicted cancers with tyrosine kinase inhibitors (TKI) is biologically and clinically different than with... 
PHASE-II TRIAL | CARBOPLATIN | EVEROLIMUS | EFFICACY | NSCLC | ONCOLOGY | MUTATED EGFR | SAFETY | CELL | IMATINIB MESYLATE | PACLITAXEL | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Withholding Treatment | Disease Progression | Time Factors | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Adult | Female | Aged | Mutation | Gefitinib | EGFR | adenocarcinoma of lung | drug resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Tumor mutational load predicts survival after immunotherapy across multiple cancer types
by Samstein, Robert M and Lee, Chung-Han and Shoushtari, Alexander N and Hellmann, Matthew D and Shen, Ronglai and Janjigian, Yelena Y and Barron, David A and Zehir, Ahmet and Jordan, Emmet J and Omuro, Antonio and Kaley, Thomas J and Kendall, Sviatoslav M and Motzer, Robert J and Hakimi, A. Ari and Voss, Martin H and Russo, Paul and Rosenberg, Jonathan and Iyer, Gopa and Bochner, Bernard H and Bajorin, Dean F and Al-Ahmadie, Hikmat A and Chaft, Jamie E and Rudin, Charles M and Riely, Gregory J and Baxi, Shrujal and Ho, Alan L and Wong, Richard J and Pfister, David G and Wolchok, Jedd D and Barker, Christopher A and Gutin, Philip H and Brennan, Cameron W and Tabar, Viviane and Mellinghoff, Ingo K and DeAngelis, Lisa M and Ariyan, Charlotte E and Lee, Nancy and Tap, William D and Gounder, Mrinal M and D’Angelo, Sandra P and Saltz, Leonard and Stadler, Zsofia K and Scher, Howard I and Baselga, Jose and Razavi, Pedram and Klebanoff, Christopher A and Yaeger, Rona and Segal, Neil H and Ku, Geoffrey Y and DeMatteo, Ronald P and Ladanyi, Marc and Rizvi, Naiyer A and Berger, Michael F and Riaz, Nadeem and Solit, David B and Chan, Timothy A and Morris, Luc G. T
Nature Genetics, ISSN 1061-4036, 02/2019, Volume 51, Issue 2, pp. 202 - 206
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer... 
CTLA-4 BLOCKADE | THERAPY | LANDSCAPE | PD-1 BLOCKADE | GENETICS & HEREDITY | SENSITIVITY | NEOANTIGENS | Usage | Research | Gene mutations | Immunotherapy | Oncology, Experimental | Cancer | Laboratories | Lung cancer | Melanoma | Histology | Metastasis | Gene expression | Cancer therapies | Patients | Survival | Metastases | Next-generation sequencing | Immune checkpoint | Biomarkers | Mutation | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas
by Arcila, Maria E and Chaft, Jamie E and Nafa, Khedoudja and Roy-Chowdhuri, Sinchita and Lau, Christopher and Zaidinski, Michael and Paik, Paul K and Zakowski, Maureen F and Kris, Mark G and Ladanyi, Marc
Clinical Cancer Research, ISSN 1078-0432, 09/2012, Volume 18, Issue 18, pp. 4910 - 4918
Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually... 
FACTOR-RECEPTOR | CANCER PATIENTS | MP-412 AV-412 | ONCOLOGY-GROUP | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | IN-SITU-HYBRIDIZATION | NEU DIFFERENTIATION FACTOR | ONCOGENE MUTATIONS | GENE COPY NUMBER | SOMATIC MUTATIONS | Lung Neoplasms - genetics | Adenocarcinoma - pathology | Prevalence | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Risk Factors | Lung Neoplasms - pathology | Male | DNA Copy Number Variations | Lung Neoplasms - epidemiology | Protein Interaction Domains and Motifs - genetics | Survival Analysis | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Aged | Mutation | Adenocarcinoma - epidemiology | Neoplasm Staging | driver oncogenes | HER2 | EGFR | ERBB2 | lung adenocarcinoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Adjuvant systemic therapy and adjuvant radiation therapy for stages i to iiia resectable non-small-cell lung cancers: American society of clinical oncology/cancer care Ontario clinical practice guideline update summary
by Kris, Mark G and Gaspar, Laurie E and Chaft, Jamie E and Kennedy, Erin B
Journal of Oncology Practice, ISSN 1554-7477, 07/2017, Volume 13, Issue 7, pp. 449 - 451
ONCOLOGY | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | United States | Humans | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Societies, Medical | Medical Oncology - standards | Carcinoma, Non-Small-Cell Lung - drug therapy | Chemotherapy, Adjuvant | Neoplasm Staging | Radiotherapy, Adjuvant | Ontario
Journal Article
Details down arrow
20. Full Text NEOSCAN: Phase II trial of neoadjuvant chemotherapy for resectable lung cancers with switch to chemo alternative in 18F-FDG PET nonresponders
by Kris, Mark G and Hellmann, Matthew David and Naidoo, Jarushka and Dunphy, Mark and Sima, Camelia S and Downey, Robert J and Travis, William D and Azzoli, Christopher G and Chaft, Jamie E
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 7515 - 7515
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.